Although there is currently no licensed vaccine against dengue virus (DENV), the chimeric yellow fever–DENV tetravalent dengue vaccine (CYD-TDV) has shown efficacy against DENV in two recent Phase III clinical trials. In this Opinion article, Guy and Jackson review the efficacy and safety data from these recent trials and discuss how interactions between the virus, pre-existing host immunity and vaccine-induced immune responses explain CYD-TDV-mediated protection.
- Bruno Guy
- Nicholas Jackson